Gilead SciencesGILD
GILD
About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees: 18,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
170% more first-time investments, than exits
New positions opened: 251 | Existing positions closed: 93
44% more funds holding in top 10
Funds holding in top 10: 18 [Q3] → 26 (+8) [Q4]
13% more capital invested
Capital invested by funds: $86.5B [Q3] → $97.9B (+$11.4B) [Q4]
5% more funds holding
Funds holding: 1,689 [Q3] → 1,772 (+83) [Q4]
1.92% more ownership
Funds ownership: 82.9% [Q3] → 84.81% (+1.92%) [Q4]
10% less call options, than puts
Call options by funds: $864M | Put options by funds: $959M
10% less repeat investments, than reductions
Existing positions increased: 619 | Existing positions reduced: 687
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$80
27%
downside
Avg. target
$108
1%
downside
High target
$123
12%
upside
11 analyst ratings
8 positive
73%
3 neutral
27%
0 negative
0%
Deutsche Bank James Shin 40% 1-year accuracy 2 / 5 met price target | 9%upside $120 | Buy Upgraded | 18 Feb 2025 |
RBC Capital Brian Abrahams 16% 1-year accuracy 13 / 79 met price target | 18%downside $90 | Sector Perform Maintained | 12 Feb 2025 |
Goldman Sachs Salveen Richter 27% 1-year accuracy 4 / 15 met price target | 13%downside $96 | Neutral Maintained | 12 Feb 2025 |
BMO Capital Evan Seigerman 67% 1-year accuracy 10 / 15 met price target | 5%upside $115 | Outperform Maintained | 12 Feb 2025 |
Wells Fargo Mohit Bansal 44% 1-year accuracy 11 / 25 met price target | 9%upside $120 | Overweight Maintained | 12 Feb 2025 |
Financial journalist opinion
Based on 50 articles about GILD published over the past 30 days
Neutral
Business Wire
1 day ago
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment o.
Positive
Zacks Investment Research
1 day ago
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Positive
Zacks Investment Research
1 day ago
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year.
Neutral
Business Wire
2 days ago
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 4 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 11 at 10:40 AM Eastern Time The live webcasts can be accessed at the company's investors page at investors.gilead.com. The replays will be available for at least 30 days following the.
Neutral
CNBC Television
3 days ago
Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
Neutral
Business Wire
3 days ago
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 19, 2025. Acceptance.
Positive
Zacks Investment Research
4 days ago
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Positive
Zacks Investment Research
4 days ago
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?
Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Positive
CNBC Television
1 week ago
Josh Brown's best stocks
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his favorite stocks in the market right now.
Positive
Zacks Investment Research
1 week ago
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™